A Day in the Life of a Medical Director
Hemodynamic monitoring
Anti vegf intravitreal injections
A 1 Risk Management Program
Compliance with the FDA Guidances on Investigator Responsibilities and the Form 1572
SCYNEXIS Proprietary and Confidential Information The Discovery and Clinical Evaluation of the Cyclophilin Inhibitor SCY-635 in HCV Infected Subjects Michael.
Safety Workshop: Part I Clinical Trial Safety and Safety Monitoring August 18, 2010 Albert Yoyin, M.D. DAIDS Regulatory Support Center (RSC) August 18,
1 US Investigator Meeting DIAS-4, Chicago, July 2011 Pharmacovigilance & Adverse Event Reporting Meredin Stoltenberg MD, PhD, DMSC Medical Safety Advisor.
1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Frida Bushnell Scientific Safety Advisor.
1 US Investigator Meeting DIAS-4, San Diego, January 2011 Pharmacovigilance & Adverse Event Reporting 15-JUL-2011 Meredin Stoltenberg MD, PhD, DMSC Medical.
Human Subject Protections in Experimentationby Thomas A. Gionis, MD JD MBA MHA FICS FRCS United States Fulbright Scholar in Law United States Fulbright.
2007 DRUG AND DEVICE FRAUD ISSUES PROSECUTING DRUG AND DEVICE VIOLATIONS-FDA REGULATORY SYMPOSIUM James G. Sheehan [email protected] 518 473-3782.
